Lantheus Holdings, Inc. (NASDAQ: LNTH) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 24.29 | EPS (ttm) | 4.14 | Insider Own | 24.66% | Shs Outstand | 65.11M | Perf Week | 0.30% |
| Market Cap | 6.55B | Forward P/E | 15.70 | EPS next Y | 6.40 | Insider Trans | 0.00% | Shs Float | 58.36M | Perf Month | 0.07% |
| Enterprise Value | 6.58B | PEG | 1.50 | EPS next Q | 1.25 | Inst Own | - | Short Float | 7.26% | Perf Quarter | -3.19% |
| Income | 275.00M | P/S | 4.21 | EPS this Y | 30.77% | Inst Trans | - | Short Ratio | 3.17 | Perf Half Y | 28.93% |
| Sales | 1.56B | P/B | 4.99 | EPS next Y | 18.29% | ROA | 11.40% | Short Interest | 4.24M | Perf YTD | 51.09% |
| Book/sh | 20.15 | P/C | 11.04 | EPS next 5Y | 16.20% | ROE | 23.27% | 52W High | 111.86 -10.11% | Perf Year | 97.78% |
| Cash/sh | 9.11 | P/FCF | 12.80 | EPS past 3/5Y | 104.28% - | ROIC | 11.03% | 52W Low | 49.67 102.44% | Perf 3Y | 61.14% |
| Dividend Est. | - | EV/EBITDA | 14.15 | Sales past 3/5Y | 18.15% 35.39% | Gross Margin | 60.14% | Volatility | 0.41% 0.49% | Perf 5Y | 287.33% |
| Dividend TTM | - | EV/Sales | 4.23 | EPS Y/Y TTM | -5.05% | Oper. Margin | 19.43% | ATR (14) | 0.77 | Perf 10Y | 962.90% |
| Dividend Ex-Date | - | Quick Ratio | 2.89 | Sales Y/Y TTM | 1.43% | Profit Margin | 17.69% | RSI (14) | 46.50 | Recom | 2.42 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.06 | EPS Q/Q | -1.27% | SMA20 | -0.10% | Beta | -0.04 | Target Price | 104.48 |
| Payout | 0.00% | Debt/Eq | 0.57 | Sales Q/Q | 2.65% | SMA50 | -1.27% | Rel Volume | 0.76 | Prev Close | 100.80 |
| Employees | 1,193 | LT Debt/Eq | 0.57 | Earnings | Nov 05 | SMA200 | 16.65% | Avg Volume | 1.34M | Price | 100.55 |
| IPO Date | Jun 25, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 18.90% 6.87% | Net Debt/EBITDA | 0.07 | Volume | 1,027,909 | Change | -0.25% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-17-26 | Reiterated | B.Riley Financial | Buy | $105 |
| Aug-04-26 | Downgrade | Truist Securities | Buy → Hold | $103 |
| Aug-04-26 | Downgrade | CJS Securities | Market Outperform → Market Perform | |
| Aug-03-26 | Reiterated | Leerink Partners | Outperform | $120 → $103 |
| Aug-03-26 | Downgrade | TD Cowen | Buy → Hold | |
| Aug-03-26 | Downgrade | William Blair | Outperform → Market Perform | $103 |
| Jul-16-26 | Reiterated | Truist Securities | Buy | $115 → $125 |
| Jul-15-26 | Reiterated | Mizuho | Outperform | $115 → $120 |
| May-27-26 | Reiterated | Mizuho | Outperform | $95 → $115 |
| May-11-26 | Reiterated | Truist Securities | Buy | $98 → $115 |
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,556 | 1,542 | 1,534 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 620 | 600 | 546 | — | — | — | — | — | — | |
| Gross Profit | 936 | 942 | 988 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 460 | 454 | 372 | — | — | — | — | — | — | |
| Research and Development | 172 | 177 | 168 | — | — | — | — | — | — | |
| Other Operating Expense | 3 | 0 | -9 | — | — | — | — | — | — | |
| Operating Income | 302 | 311 | 457 | — | — | — | — | — | — | |
| Interest Expense | 20 | 20 | 20 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 81 | 23 | -6 | — | — | — | — | — | — | |
| Net Income Before Taxes | 362 | 314 | 431 | — | — | — | — | — | — | |
| Income Taxes | 88 | 80 | 119 | — | — | — | — | — | — | |
| Consolidated Net Income | 275 | 234 | 312 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 275 | 234 | 312 | — | — | — | — | — | — | |
| Net Income | 275 | 234 | 312 | — | — | — | — | — | — | |
| EPS (Recurring) | 4.21 | 3.46 | 4.52 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.21 | 3.46 | 4.52 | — | — | — | — | — | — | |
| EPS (Diluted) | 4.14 | 3.41 | 4.36 | — | — | — | — | — | — | |
| EBITDA | 465 | 404 | 515 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 24.29 | 19.52 | 20.52 | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.20 | 2.89 | 4.02 | — | — | — | — | — | — | |
| Gross Margin | 60.15 | 61.09 | 64.41 | — | — | — | — | — | — | |
| Operating Margin | 19.41 | 20.17 | 29.79 | — | — | — | — | — | — | |
| Net Margin | 17.67 | 15.18 | 20.34 | — | — | — | — | — | — | |
| Shares Outstanding | 65 | 67 | 69 | — | — | — | — | — | — | |
| Market Capitalization | 6,536 | 4,459 | 6,173 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PATEL RAJIV A | other: Member of a Group Owning 10% | Aug 20 '25 | Sale | 56.15 | 3,365,000 | 188,944,750 | 3,477,227 | Aug 21 |
| FARALLON PARTNERS L L C/CA | 10 percent owner, other: Member of a Group Owning 10% | Aug 20 '25 | Sale | 56.15 | 3,365,000 | 188,944,750 | 3,477,227 | Aug 21 |
| FARALLON PARTNERS L L C/CA | 10 percent owner, other: Member of a Group Owning 10% | Aug 19 '25 | Sale | 55.34 | 41,000 | 2,268,940 | 6,842,227 | Aug 21 |
| PATEL RAJIV A | other: Member of a Group Owning 10% | Aug 19 '25 | Sale | 55.34 | 41,000 | 2,268,940 | 6,842,227 | Aug 21 |
| Blanchfield Paul | President | Aug 13 '25 | Sale | 53.57 | 3,060 | 163,924 | 108,214 | Aug 15 |
| Niedzwiecki Daniel | See Remarks | Jun 13 '25 | Sale | 78.74 | 6,000 | 472,440 | 87,057 | Jun 17 |
| McHugh Julie | Director | Jun 09 '25 | Sale | 81.62 | 5,192 | 423,771 | 25,962 | Jun 11 |
| Marshall Robert J. Jr. | CFO and Treasurer | Jun 09 '25 | Option Exercise | 49.93 | 14,773 | 737,616 | 128,633 | Jun 11 |
| Marshall Robert J. Jr. | CFO and Treasurer | Jun 09 '25 | Sale | 83.00 | 39,773 | 3,301,296 | 88,860 | Jun 11 |
| Blanchfield Paul | President | Jun 05 '25 | Sale | 79.65 | 6,599 | 525,610 | 111,792 | Jun 09 |
| Niedzwiecki Daniel | See Remarks | Jun 05 '25 | Sale | 79.65 | 6,000 | 477,900 | 93,057 | Jun 09 |
| Heino Mary Anne | Director | Jun 02 '25 | Sale | 76.83 | 26,066 | 2,002,570 | 318,650 | Jun 04 |
| Marshall Robert J. Jr. | CFO and Treasurer | Mar 17 '25 | Sale | 100.52 | 10,000 | 1,005,200 | 113,860 | Mar 19 |
| Heino Mary Anne | Director | Mar 13 '25 | Sale | 100.13 | 2 | 200 | 8,618 | Mar 17 |
| Heino Mary Anne | Director | Jun 07 '24 | Sale | 81.26 | 1 | 81 | 37,719 | Mar 17 |